Search Results
You are looking at 1 - 6 of 6 items for
- Author: M. C. Slootweg x
- Refine by access: All content x
Search for other papers by M C Slootweg in
Google Scholar
PubMed
Search for other papers by J P Salles in
Google Scholar
PubMed
Search for other papers by C Ohlsson in
Google Scholar
PubMed
Search for other papers by C P de Vries in
Google Scholar
PubMed
Search for other papers by M J E Engelbregt in
Google Scholar
PubMed
Search for other papers by J C Netelenbos in
Google Scholar
PubMed
Abstract
Growth hormone (GH) exerts direct differentiative and proliferative effects on osteoblasts. We studied 125I-labeled human (h) GH binding to primary mouse osteoblasts derived from collagenase-treated 18-day fetal mouse calvaria. Scatchard analysis of the data revealed a single class of high affinity GH receptors (apparent K a= 5·74 × 109 m −1) with 2200 sites per cell. Affinity cross-linking and SDS-PAGE electrophoresis showed two bands with apparent molecular masses of 120 and 70 kDa. Mouse osteoblasts express GH receptor mRNA with gene transcripts of 4·2 and 1·2 kb, at levels which reach approximately 1/6 of those in mouse liver and 1/3 of those in mouse muscle. Two populations of undifferentiated and diffentiated osteoblasts, obtained by sequential collagenase digestion of mouse calvaria, were used to study the relationship between osteoblastic phenotype and GH receptor expression. Although the affinity of the receptors in undifferentiated and differentiated cells was the same, the capacity was significantly higher (1·45 ± 1·0% vs 2·39 ± 0·9%, P=0·03) in differentiated cells. This stresses the specific importance of the osteoblast as a target cell for GH. The differentiating potential of the vitamin A derivative retinoic acid was subsequently used experimentally to induce differentiation in the cells. Retinoic acid increased 125I-hGH binding to preosteoblasts (153%, P=0·02). Together, these data demonstrate the presence of a high affinity GH receptor in mouse osteoblasts which is related to differentiation.
Journal of Endocrinology (1996) 150, 465–472
Search for other papers by M.C. Slootweg in
Google Scholar
PubMed
Search for other papers by S.C. van Buul-Offers in
Google Scholar
PubMed
Search for other papers by M.P.M. Herrmann-Erlee in
Google Scholar
PubMed
Search for other papers by J.M. van der Meer in
Google Scholar
PubMed
Search for other papers by S.A. Duursma in
Google Scholar
PubMed
ABSTRACT
More evidence has recently been obtained indicating that growth hormone (GH) has a direct effect on bone. However, it is not clear which cell type reacts to the hormone. The present study used osteoblast-like cells derived from sequentially digested fetal mouse calvaria. Separately cultured tractions resulted in populations enriched in cells with a more or a less differentiated phenotype. The results showed that GH acts on the cells released last, i.e. those with more characteristics of the osteoblast. In these cells, GH induced strong mitogenic activity. Prolactin was not active.
Search for other papers by M. C. Slootweg in
Google Scholar
PubMed
Search for other papers by C. M. Hoogerbrugge in
Google Scholar
PubMed
Search for other papers by T. L. de Poorter in
Google Scholar
PubMed
Search for other papers by S. A. Duursma in
Google Scholar
PubMed
Search for other papers by S. C. van Buul-Offers in
Google Scholar
PubMed
ABSTRACT
Specific binding to and proliferative actions of insulinlike growth factors-I and -II (IGF-I and -II) on fetal mouse osteoblasts were tested. Membranes of mouse osteoblasts were shown by binding competition studies to possess specific binding sites for IGF-I and IGF-II. When IGF-I was used as a tracer, half-maximal displacement was obtained with 1·11 μg IGF-I/1 and with 14 μg IGF-II/1. Displacement of 125I-labelled IGF-I was accomplished with 2·33 μg IGF-II/1 and with 55 μg IGF-I/1. Affinity cross-linking showed bands of 130 kDa 125I-labelled IGF-I and 260 kDa 125I-labelled IGF-II under reducing conditions, further indicating the presence of classical type-I and -II receptor sites on mouse osteoblasts. Mitogenic effects of IGFs were weak; a combination with epidermal growth factor or fibroblast growth factor showed strong synergistic action however. The possibility of autocrine/paracrine actions of IGFs is discussed.
Journal of Endocrinology (1990) 125, 271-277
Search for other papers by M. C. Slootweg in
Google Scholar
PubMed
Search for other papers by W. W. Most in
Google Scholar
PubMed
Search for other papers by E. van Beek in
Google Scholar
PubMed
Search for other papers by L. P. C. Schot in
Google Scholar
PubMed
Search for other papers by S. E. Papapoulos in
Google Scholar
PubMed
Search for other papers by C. W. G. M. Löwik in
Google Scholar
PubMed
ABSTRACT
Insulin-like growth factor-I (IGF-I) is a potent stimulator of bone formation. Whether this growth factor also induces bone resorption has not been studied in detail. We used two organ culture systems to examine the direct effect of IGF-I on bone resorption. Fetal mouse radii/ulnae, containing mature osteoclasts, showed no response to IGF-I, indicating that osteoclastic activity is not influenced by IGF-I. Fetal mouse metacarpals/metatarsals, containing just osteoclast precursors and progenitors, showed an increase in resorption in response to IGF-I, indicating that IGF-I stimulates the formulation of osteoclast precursors/progenitors and thereby increases the number of osteoclasts.
Interleukin-6 (IL-6) has been hypothesized to be a mediator of bone resorptive agents such as parathyroid hormone (PTH). Both radii/ulnae and metacarpals/metatarsals reacted to IGF-I with an increase in IL-6 production. IL-6 production by UMR-106 osteogenic osteosarcoma cells was positively modulated by IGF-I, indicating that osteoblasts are likely to be the cells responsible for increased IL-6 production by the bones, and that IL-6 might be a mediatory of IGF-I-stimulated bone resorption.
Journal of Endocrinology (1992) 132, 433–438
Search for other papers by M. C. Slootweg in
Google Scholar
PubMed
Search for other papers by S. C. van Buul-Offers in
Google Scholar
PubMed
Search for other papers by C. M. Hoogerbrugge in
Google Scholar
PubMed
Search for other papers by M. P. M. Herrmann-Erlee in
Google Scholar
PubMed
Search for other papers by A. J. M. van den Eijnden-van Raaij in
Google Scholar
PubMed
Search for other papers by S. A. Duursma in
Google Scholar
PubMed
Search for other papers by E. J. J. van Zoelen in
Google Scholar
PubMed
ABSTRACT
Bone matrix contains a variety of growth factors, but little is known of osteoblastic production of such materials. The present study assesses growth factor activity, chromatographed on acidic Bio-Gel P-100, secreted into conditioned media of primary cultures of fetal mouse calvaria. The cultures produced insulin-like growth factor-I (IGF-I), determined by radioimmuno-assay of molecular weights 20 and 10 kDa. IGF-II, determined by radioreceptor assay, was present at 20–29 and 7 kDa. The IGF peaks at 20, 10 and 7 kDa were all mitogenic in MCF-7 cells. Proteins of several different molecular weights were also present that specifically bound IGF-I and IGF-II. Transforming growth factor-β (TGF-β), assayed in a system for inhibition of growth, was also produced. Both activated and latent forms were present, and part of the TGF-β was TGF-β2. The absence of mitogenic activity in the bmolecular range of platelet-derived growth factor, assayed in 3T3 fibroblasts, makes it unlikely that mouse osteoblasts produce this growth factor.
Journal of Endocrinology (1990) 124, 301–309
Search for other papers by M.C. Slootweg in
Google Scholar
PubMed
Search for other papers by A.G.H. Ederveen in
Google Scholar
PubMed
Search for other papers by L.P.C. Schot in
Google Scholar
PubMed
Search for other papers by W.G.E.J. Schoonen in
Google Scholar
PubMed
Search for other papers by H.J. Kloosterboer in
Google Scholar
PubMed
ABSTRACT
Oestrogens play an important role in bone metabolism; they preserve bone mass after the menopause. Their action in bone has recently been shown to be, partly, a direct one, as oestrogen receptors and their effects have been demonstrated in bone cells. The role of progestogens in bone metabolism is less clear. In this study it has been shown that 17β-oestradiol exerts only a small, although not significant, stimulatory action with regard to SaOS-2 human osteosarcoma cell proliferation. A pure progestogen (Org 2058) has no effect when added alone. In combination with 17β-oestradiol, however, it has a highly synergistic action on SaOS-2 cell proliferation. The same effect was observed in primary rat osteoblasts, showing that this synergism is a general phenomenon in osteoblastic cells. High numbers of oestrogen and progestogen receptors have been demonstrated in SaOS-2 cells, indicating that the effects of these steroids are mediated via the normal route of steroid receptors. These data provide a cellular basis for the clinically recognized positive effect of oestrogen/progestogen combinations on bone formation.
